CRIS vs. CDTX, NTGN, XFOR, CDXS, ACHV, RIGL, RGLS, SGMO, VSTM, and FBIO
Should you be buying Curis stock or one of its competitors? The main competitors of Curis include Cidara Therapeutics (CDTX), Neon Therapeutics (NTGN), X4 Pharmaceuticals (XFOR), Codexis (CDXS), Achieve Life Sciences (ACHV), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Sangamo Therapeutics (SGMO), Verastem (VSTM), and Fortress Biotech (FBIO). These companies are all part of the "medical" sector.
Curis (NASDAQ:CRIS) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings.
Cidara Therapeutics has higher revenue and earnings than Curis. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
Curis has a beta of 3.59, suggesting that its stock price is 259% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.
Curis currently has a consensus target price of $37.33, suggesting a potential upside of 260.36%. Cidara Therapeutics has a consensus target price of $71.25, suggesting a potential upside of 461.47%. Given Cidara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cidara Therapeutics is more favorable than Curis.
In the previous week, Cidara Therapeutics had 3 more articles in the media than Curis. MarketBeat recorded 4 mentions for Cidara Therapeutics and 1 mentions for Curis. Curis' average media sentiment score of 1.88 beat Cidara Therapeutics' score of 0.87 indicating that Curis is being referred to more favorably in the media.
Cidara Therapeutics has a net margin of -73.46% compared to Curis' net margin of -486.45%. Cidara Therapeutics' return on equity of -201.62% beat Curis' return on equity.
Curis received 249 more outperform votes than Cidara Therapeutics when rated by MarketBeat users. However, 70.24% of users gave Cidara Therapeutics an outperform vote while only 67.65% of users gave Curis an outperform vote.
30.0% of Curis shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 5.7% of Curis shares are held by company insiders. Comparatively, 7.4% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Cidara Therapeutics beats Curis on 13 of the 18 factors compared between the two stocks.
Get Curis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
